ACHE and early-onset autosomal dominant Alzheimer disease: Arslan et al. [79] state that farnesene derivatives show considerable anti-AChE activity when combined with β-amyloids, peptides used in the treatment of Alzheimer’s disease, exhibiting inhibitory activity equivalent to 474.80 μm L−1 after 24 h of exposure and 413.80 μm L−1 after 48 h.